 - To evaluate the clinical efficacy of docetaxel and vandetanib relative to docetaxel alone in patients with platinum-resistant, recurrent, refractory, or progressivepersistent ovarian epithelial, primary peritoneal, or fallopian tube cancer, as measured by progression-free survival. 